Olr653 inhibitors are a class of chemical compounds specifically designed to inhibit the activity of the Olr653 receptor, a type of olfactory receptor. These receptors are part of the larger G protein-coupled receptor (GPCR) family, which are integral to various signal transduction pathways. The Olr653 receptor is typically involved in the detection of specific odorants, initiating a cascade of intracellular events upon activation that ultimately result in the perception of smell. Inhibitors of Olr653 are crafted to interfere with this process, preventing the receptor from binding to its natural ligands and thereby disrupting the signaling pathway.
Chemically, Olr653 inhibitors can vary widely in structure, but they generally share certain features that enable them to effectively bind to the receptor's active site. These molecules often exhibit a high degree of specificity, ensuring that they selectively inhibit Olr653 without affecting other olfactory receptors or GPCRs. The design of these inhibitors involves a detailed understanding of the receptor's three-dimensional structure, often achieved through techniques such as X-ray crystallography or computational modeling. By identifying key binding sites and interactions within the receptor, chemists can design molecules that fit precisely into the receptor's active site, blocking its normal function. Research into Olr653 inhibitors not only enhances our understanding of olfactory processes but also contributes to the broader field of GPCR signaling, providing insights into the molecular mechanisms that underlie receptor function and inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, potentially disrupting proteins in the MAPK/ERK pathway. | ||||||
BYL719 | 1217486-61-7 | sc-391001 sc-391001A sc-391001B sc-391001C sc-391001D sc-391001E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $391.00 $597.00 $755.00 $1192.00 $5000.00 $9370.00 | 2 | |
PI3K inhibitor, potentially affecting proteins involved in the AKT/mTOR signaling pathway. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, potentially affecting proteins in angiogenesis, oncogenesis, and the tumor microenvironment. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, specifically targeting T790M mutation, potentially affecting proteins in mutated EGFR pathways. | ||||||
BAY 80-6946 | 1032568-63-0 | sc-503264 | 5 mg | $562.00 | ||
PI3K inhibitor, potentially altering proteins involved in cell signaling and survival pathways. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
BRAF inhibitor, potentially affecting proteins involved in the MAPK/ERK pathway. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor, potentially impacting protein degradation and cell cycle regulation. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Inhibits multiple tyrosine kinases, including VEGFR, potentially affecting angiogenesis-related proteins. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Inhibits cyclin-dependent kinases 4 and 6, potentially affecting cell cycle-related proteins. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
ALK inhibitor, potentially affecting proteins in ALK-driven signaling pathways. | ||||||